Erythromycin

Manufacturer
VersaPharm Incorporated | Ei LLC
Effective date
2014-10-09
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
4
Source
legacy-cache
Hydrated at
2026-08-02 01:34:53

Label at a glance#

ProductErythromycin
Active ingredientERYTHROMYCIN
Label structure13 sections

Indications and uses

Erythromycin Pledgets USP, 2% are indicated for the topical treatment of acne vulgaris.

Dosage and administration

The Erythromycin Pledgets USP, 2% should be rubbed over the affected area twice a day (morning and evening) after skin is thoroughly washed with warm water and soap and patted dry. Acne lesions on the face, neck, shoulder, chest, and back may be treated in this manner. Additional pledgets may be used, if needed. Each pledget should be used once and discarded. Wash hands after application. Close jar tightly after e...

Storage and handling

Store at 20° - 25°C (68° - 77°F) [See USP Controlled Room Temperature].

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only
For Dermatologic Use Only
Not for Ophthalmic Use

DESCRIPTION

DESCRIPTION SECTION

Erythromycin Pledgets USP, 2% contain erythromycin, USP for topical dermatologic use. Erythromycin is a macrolide antibiotic produced from a strain of Saccaropolyspora erythraea (formerly Streptomyces erythreus). It is a base and readily forms salts with acids. Chemically, erythromycin is C37H67NO13. It has the following structural formula:

Chemical Structure
Chemical Structure

Molecular weight of 733.94

The chemical name for erythromycin is (3R*,4S*,5S*,6R*,7R*,9R*,11R*, 12R*,13S*,14R*)-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy] oxacyclotetradecane-2,10-dione.

Erythromycin is a white or slightly yellow, crystalline powder, slightly soluble in water, soluble in alcohol, in chloroform, and in ether. It is odorless or practically odorless. It has a pH range between 8.0 and 10.5 in a methanol and water solution prepared by diluting 1 volume of a methanol solution, containing 40 mg per mL, with 19 volumes of water.

Each mL of expressible liquid contains 20 mg erythromycin in a base of alcohol (68.5%) (denatured with tert-butyl alcohol and denatonium benzoate), propylene glycol and citric acid to adjust pH. Each pledget is filled to contain 0.8 mL of erythromycin topical solution.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

The exact mechanism by which erythromycin reduces lesions of acne vulgaris is not fully known: however, the effect appears to be due in part to the antibacterial activity of the drug.

MICROBIOLOGY

MICROBIOLOGY SECTION

Erythromycin acts by inhibition of protein synthesis in susceptible organisms by reversibly binding to 50 S ribosomal subunits, thereby inhibiting translocation of aminoacyl transfer-RNA and inhibiting polypeptide synthesis. Antagonism has been demonstrated in vitro between erythromycin, and lincomycin, chloramphenicol, and clindamycin.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Erythromycin Pledgets USP, 2% are indicated for the topical treatment of acne vulgaris.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Erythromycin Pledgets USP, 2% are contraindicated in those individuals who have shown hypersensitivity to any of its components.

WARNINGS

WARNINGS SECTION

Pseudomembranous colitis has been reported with nearly all antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.

Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is one primary cause of "antibiotic-associated colitis". After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against C. difficile colitis.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

For topical use only; not for ophthalmic use. Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating, or abrasive agents.

The use of antibiotic agents may be associated with the overgrowth of antibiotic-resistant organisms. If this occurs, discontinue use and take appropriate measures.

Avoid contact with eyes and all mucous membranes.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Patients using Erythromycin Pledgets USP, 2% should receive the following information and instructions:

  1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes, nose, mouth, and all mucous membranes.
  2. This medication should not be used for any disorder other than that for which it was prescribed.
  3. Patients should not use any other topical acne medication unless otherwise directed by their physician.
  4. Patients should report to their physician any signs of local adverse reactions.

Carcinogenesis, mutagenesis, and impairment of fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No animal studies have been performed to evaluate the carcinogenic and mutagenic potential or effects on fertility of topical erythromycin. However, long-term (2-year) oral studies in rats with erythromycin ethylsuccinate and erythromycin base did not provide evidence of tumorigenicity. There was no apparent effect on male or female fertility in rats fed erythromycin (base) at levels up to 0.25% of diet.

Pregnancy

PREGNANCY SECTION

Teratogenic effects

TERATOGENIC EFFECTS SECTION

Pregnancy Category B

SPL UNCLASSIFIED SECTION

There was no evidence of teratogenicity or any other adverse effect on reproduction in female rats fed erythromycin base (up to 0.25% diet) prior to and during mating, during gestation and through weaning of two successive litters.

There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed. Erythromycin has been reported to cross the placental barrier in humans, but fetal plasma levels are generally low.

Nursing women

NURSING MOTHERS SECTION

It is not known whether erythromycin is excreted in human milk after topical application. However, erythromycin is excreted in human milk following oral and parenteral erythromycin administration. Therefore, caution should be exercised when erythromycin is administered to a nursing women.

Pediatric use

PEDIATRIC USE SECTION

Safety and effectiveness of this product in pediatric patients have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following local adverse reactions have been reported occasionally: peeling, dryness, itching, erythema, and oiliness. Irritation of the eyes and tenderness of the skin have also been reported with topical use of erythromycin. Generalized urticarial reactions, possibly related to the use of erythromycin, which required systemic steroid therapy have been reported.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The Erythromycin Pledgets USP, 2% should be rubbed over the affected area twice a day (morning and evening) after skin is thoroughly washed with warm water and soap and patted dry. Acne lesions on the face, neck, shoulder, chest, and back may be treated in this manner. Additional pledgets may be used, if needed. Each pledget should be used once and discarded. Wash hands after application. Close jar tightly after each use. Drying and peeling may be controlled by reducing the frequency of applications.

HOW SUPPLIED

HOW SUPPLIED SECTION

Erythromycin Pledgets USP, 2% are available in a plastic jar containing 60 pledgets - NDC 61748-202-60.

Each pledget is filled to contain 0.8 mL of erythromycin topical solution, 2%.

Keep jar tightly closed.

STORAGE AND HANDLING SECTION

Store at 20° - 25°C (68° - 77°F) [See USP Controlled Room Temperature].

SPL UNCLASSIFIED SECTION

Marketed by:
VersaPharm Incorporated
Marietta, GA 30062

VersaPharm LogoVersaPharm Logo
Manufactured by:
Ei LLC 
Kannapolis, NC 28083


IS1VP20260-01
Revised: 01-14-2014
P001

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL-Container Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 61748-202-60

ERYTHROMYCIN

PLEDGETS USP, 2%

For External Use.

Avoid contact with eyes.

Rx Only

60 Pledgets

Principal Display Panel - 60 Pledget Jar Label
Principal Display Panel - 60 Pledget Jar Label

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
61748-202-602022-07-25C16284748780-19d75b9d1-152a-f424-e053-dadaa90a57ceERYTHROMYCIN PLEDGETS USP, 2%
61748-202-602020-01-31C16284748780-19d75b9d1-152a-f424-e053-dadaa90a57ceERYTHROMYCIN PLEDGETS USP, 2%

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
61748-202-60EA - Each61748-2023da16cb4-b287-4b4d-9054-6e8874eba34012012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
ERYTHROMYCINACTIVE INGREDIENT63937KV33D4
ERYTHROMYCINACTIVE MOIETY63937KV33D4
ALCOHOLINACTIVE INGREDIENT3K9958V90M4
ANHYDROUS CITRIC ACIDINACTIVE INGREDIENTXF417D3PSL4
PROPYLENE GLYCOLINACTIVE INGREDIENT6DC9Q167V34

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 4 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
61748-20261748-202-60

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 4 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 4 · 201 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3OINTMENT, AUGMENTED / TOPICAL714 mgExact identifier — unii candidate
81 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MGEL, METERED / TRANSDERMAL3675 mgExact identifier — unii candidate
59 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MDROPS / ORAL210 mg/1mlExact identifier — unii candidate
59 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3FILM / BUCCAL1.48 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SUSPENSION / AURICULAR (OTIC)10 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MPASTE / DENTAL1.8 %w/wExact identifier — unii candidate
59 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3FILM, EXTENDED RELEASE / TRANSDERMAL58.13 mgExact identifier — unii candidate
81 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MGEL / TRANSDERMAL7360 mgExact identifier — unii candidate
59 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLINJECTION, SOLUTION / SUBCUTANEOUS25 mgExact identifier — unii candidate
61 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION / OPHTHALMIC1 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MINJECTION / INTRAVENOUS92 %w/vExact identifier — unii candidate
59 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3FILM, SOLUBLE / BUCCAL5 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3TABLET, FILM COATED / ORAL96 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SUSPENSION / RECTAL90400 mgExact identifier — unii candidate
81 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSOLUTION / OPHTHALMIC0.09 %w/vExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSUSPENSION/ DROPS / OPHTHALMIC0.05 %w/vExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLTABLET, CHEWABLE / ORAL4 mgExact identifier — unii candidate
61 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CAPSULE / ORAL1072 mgExact identifier — unii candidate
81 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MGEL / TOPICAL9971 mgExact identifier — unii candidate
59 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MLIQUID / ORAL3563 mgExact identifier — unii candidate
59 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLINJECTION / SUBCUTANEOUS101 mgExact identifier — unii candidate
61 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3LOTION / TOPICAL3392 mgExact identifier — unii candidate
81 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSOLUTION / TRANSDERMAL49.37 %w/vExact identifier — unii candidate
59 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3INJECTION / INTRAVENOUS16624 mgExact identifier — unii candidate
81 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MINJECTION, SOLUTION / SUBCUTANEOUS6.1 %v/vExact identifier — unii candidate
59 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CAPSULE, EXTENDED RELEASE / ORAL8 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SPRAY / NASAL5 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3TABLET / ORAL64 mgExact identifier — unii candidate
81 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLFILM / BUCCAL9 mgExact identifier — unii candidate
61 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SHAMPOO, SUSPENSION / TOPICAL2 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLINJECTION / INTRAVENOUS1152 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLFILM, SOLUBLE / BUCCAL2 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLPASTE / ORAL26 mgExact identifier — unii candidate
61 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MCONCENTRATE / ORAL198 mgExact identifier — unii candidate
59 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSOLUTION / OPHTHALMIC0.5 %w/vExact identifier — unii candidate
59 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSOLUTION / TOPICAL2445 mgExact identifier — unii candidate
59 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MAEROSOL, METERED / RESPIRATORY (INHALATION)26664 mgExact identifier — unii candidate
59 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3TABLET, FILM COATED, EXTENDED RELEASE / ORAL19 mgExact identifier — unii candidate
81 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MLIQUID / RESPIRATORY (INHALATION)5 %w/wExact identifier — unii candidate
59 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MINJECTION, SOLUTION / INTRAVENOUS6405 mgExact identifier — unii candidate
59 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3INJECTION, SOLUTION / INTRAMUSCULAR4000 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3TABLET, COATED / ORAL16 mgExact identifier — unii candidate
81 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLINJECTION, SOLUTION, CONCENTRATE / INTRAVENOUS81 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSPRAY / TOPICAL0.01 %w/wExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS414 mgExact identifier — unii candidate
61 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MAEROSOL / NASAL20 mgExact identifier — unii candidate
59 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3INJECTION / INTRAMUSCULAR7459 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CAPSULE, COATED, EXTENDED RELEASE / ORALNAExact identifier — unii candidate
81 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSUSPENSION, EXTENDED RELEASE / ORAL62 mgExact identifier — unii candidate
61 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSPRAY, METERED / SUBLINGUAL29 mgExact identifier — unii candidate
59 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSUSPENSION / RECTAL904 mgExact identifier — unii candidate
61 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SUSPENSION / ORAL27120 mgExact identifier — unii candidate
81 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLFILM, SOLUBLE / ORAL7 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSPRAY / NASAL5 mgExact identifier — unii candidate
61 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3GEL / TRANSDERMAL500 mgExact identifier — unii candidate
81 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MINJECTION, EMULSION / INTRAVENOUS520 mgExact identifier — unii candidate
59 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3OINTMENT / RECTAL27 mgExact identifier — unii candidate
81 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLTABLET / SUBLINGUAL36 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLCAPSULE, LIQUID FILLED / ORAL360 mgExact identifier — unii candidate
61 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3INJECTION, SOLUTION / SUBCUTANEOUS1.4 %w/vExact identifier — unii candidate
81 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A090215-001ERYTHROMYCINERYTHROMYCIN2%SWAB / TOPICALAT2010-05-12

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A090215-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-1284e616aacf4f…
2026-08-18 06:07:402026-07A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-12caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-12011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-1231067a03dcf5…
2025-08-23 18:47 UTC2025-08A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-126a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-12fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-12b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-1203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-122680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-125bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-12d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-12d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-1279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-12301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-121e350fbaab3a…
2024-05-31 18:47 UTC2024-05A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-128072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-125c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-125d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-124b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-1274a2ff9319b5…
2022-03-09 01:35 UTC2022-03A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-12bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-12782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-1287673890dc5c…
2021-03-12 10:30 UTC2021-03A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-125aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-128869cabd3fbd…
2020-11-12 02:37 UTC2020-11A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-12c0c555d07b60…
2019-12-14 00:12 UTC2019-12A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-123f01610625f2…
2019-09-15 20:21 UTC2019-09A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-12b00525d2431f…
2019-07-19 19:46 UTC2019-07A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-12ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-126a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-121c564ffb4f44…
2023-12-20 04:57 UTC2023-12A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-12ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-12a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-129b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-12a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-123f0d92c62455…
2023-05-13 08:27 UTC2023-05A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-12053a50430f4f…
2023-01-26 05:58 UTC2023-01A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-123bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-123a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A090215-001ERYTHROMYCIN2%SWAB / TOPICALAT2010-05-12f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A090215-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A090215-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A090215-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A090215-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A090215-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A090215-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A090215-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A090215-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A090215-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A090215-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A090215-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A090215-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A090215-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A090215-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A090215-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A090215-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A090215-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A090215-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A090215-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A090215-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A090215-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A090215-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A090215-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A090215-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A090215-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A090215-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A090215-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A090215-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A090215-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A090215-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A090215-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A090215-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A090215-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A090215-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A090215-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A090215-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A090215-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A090215-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A090215-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A090215-001AT1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
d9ab9f57-9375-4f95-b77e-60186a44e96f7a4eeb39-beb4-4554-a5ab-e752887433e12022-07-25Warnings, Adverse reactionsExact identifier
spl set id: 7a4eeb39-beb4-4554-a5ab-e752887433e1

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.